The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that ...

Westbury breast cancer survivor Lexy Mealing has been honored by the American Cancer Society for going above and beyond the ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Bachelorette' alum Katie Thurston responded to backlash over sending her dog Charlie to training while navigating her cancer ...

Financial Guidance Based on its current operating plan, Arvinas believes its cash, cash equivalents, and marketable securities as of March 31, 2025, is sufficient to fund planned operating expenses ...

The findings of this study suggest a narrowing of racial and ethnic disparities in receipt of ERBB2 (formerly HER2 or HER2/neu)-targeted therapies over time among older Medicare beneficiaries with ...

Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

Breast cancer deaths among women ages 20-49 declined significantly between 2010 and 2020, according to a new study.

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.